TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06227390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy
Description: 2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy
Description: 2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy
Description: 2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy
Description: 2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy
Description: 2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy
Description: 2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
Study: NCT04158024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
Study: NCT05804435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNod™ System
Description: The iNod™ Ultrasound Imaging System enables visualization of endobronchial lesions, peripheral lung nodules, or lung masses (referred to as lesions) using R-EBUS and performance of lung biopsy under direct R-EBUS visualization.
Study: NCT05472155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulb syringe
Description: Suctioning with a bulb syringe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction catheter
Description: Suctioned with a suction catheter
Study: NCT05709652

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aortic CTA, .23s
Description: Aortic CTA performed with short (0.23 sec) gantry rotation time.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Aortic CTA, .28s
Description: Aortic CTA performed with standard (.28 sec) gantry rotation time.
Study: NCT06301113

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CBD infused candy
Description: 300 Nano mg CBD Candy cherry flavor

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar free Candy
Description: Raspberry flavored sugar free candy
Study: NCT05294835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine infusion
Study: NCT05068037

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACUPUNCTURE
Description: standard acupuncture TCM (analgesia, vomiting)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ANTIEMETICS
Description: NO ACUPUNCTURE, WITH ANTIEMETICS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NOTHING
Description: NO ACUPUNCTURE, NO ANTIEMETICS
Study: NCT05029934

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: use of EndoClot
Description: deployment of EndoClot adhesive spray

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: use of EndoClot
Description: deployment of EndoClot adhesive spray
Study: NCT06347718

Intervention type: DRUG
Group type: OTHER
Intervention: anti-CD19 CAR T cell therapy
Description: Single-dose
Study: NCT05709873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rehearsal therapy
Description: Therapy to reduce nightmares, delivered via videoconference sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rehearsal therapy
Description: Therapy to reduce nightmares, delivered via videoconference sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted dream control
Description: Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
Study: NCT04946136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait modification
Description: Individualized gait modifications guided by real-time visual feedback of knee load
Study: NCT05976724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS, exercise
Description: TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS, exercise
Description: TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilisation
Description: Each participant was tested with sustained manual glides in each of the possible directions during active wrist flexion and extension from the seated position. For the lateral glide, the therapist stabilises the lateral aspect of the distal radius using the first web-space. And glides the proximal row of carpal bones laterally (towards the thumb) using the first web-space of the other hand, following the joint line. For the medial glide, the therapist stabilises the medial aspect of the distal ulna using the first web-space. And glides the proximal row of carpal bones medially (away from the thumb) using the first web-space of the other hand, following the joint line.
Study: NCT05118477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring system
Description: Patients will use AMS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory monitoring system
Description: Patients will use AMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active alerting system
Description: Clinical staff alerted if AMS detects deterioration
Study: NCT05631535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change program with a very-low-energy diet
Description: The intervention will consist of two phases. In the first phase, the participants receive weekly visits for two months. During these visits, a nutritionist will take the participants' weight and abdominal circumference measurements, and each one will receive a meal plan with a very low-energy diet (800 kcal/d). The second phase will implement in the third and fourth months, and nutritional counseling will continue to be provided every week in the third and biweekly in the fourth month. In this second phase, a gradual reintroduction to low-energy dietary meal plans (1200-1800 kcal/d) will perform. In addition, a specially adapted Diabetes Prevention Program for a very low-energy diet will implement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle change program with a low-energy diet
Description: The structure (frequency of nutritional counseling, number of sessions, time of sessions, etc.) in this group will be the same as that of the intervention group, and a modified Diabetes Prevention Program will also provide. From the beginning of the study will recommend meal plans with a low-energy diet (1200-1800 kcal).
Study: NCT05174286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~The investigators will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral as Usual (RAU)
Description: Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
Study: NCT05396976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga and Muscle Relaxation Exercise Practices
Description: Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga and Muscle Relaxation Exercise Practices
Description: Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga and Muscle Relaxation Exercise Practices
Description: Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
Study: NCT05037266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine Janssen (Ad26.COV2-S)
Description: one dose (0.5mL) at D1 and one dose (0.5mL) at D57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine Janssen (Ad26.COV2-S)
Description: one dose (0.5mL) at D1 and one dose (0.5mL) at D57
Study: NCT06130878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic exercise
Description: A multicomponent rhythmic physical training will be carried out, with a predominance of QMT, following the principles of Animal Flow \[46\] and including the following components: wrist mobilizations; activations; specific stretching positions; special locomotor movements or traveling forms; interruptions and transitions with dynamic movements and choreographic sequences of Flow. Aspects related to the control of intensity, volume and progression strategy have yet to be defined.
Study: NCT06443320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: videodrama sessions
Description: Patients will benefit from videodrama sessions, one per week for 9 sessions
Study: NCT05553613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG Oral Tablet
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT05927142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Human anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
Study: NCT06261619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adult Sotair Device
Description: Adult Sotair® device employs a flow limiting valve mechanism.
Study: NCT06185972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonalleve Focused Ultrasound Device
Description: Sonalleve Focused Ultrasound Device
Study: NCT05703763

Intervention type: DIAGNOSTIC_TEST
Intervention: Applanation tonometry
Description: Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~* Superficial temporal artery to frontal temporal artery~* Common carotid artery to frontal temporal artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Applanation tonometry
Description: Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~* Superficial temporal artery to frontal temporal artery~* Common carotid artery to frontal temporal artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized GCA assessment
Description: Clinical assessment, blood test review, high-resolution temporal artery ultrasound using a 24mHz probe.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized GCA assessment
Description: Clinical assessment, blood test review, high-resolution temporal artery ultrasound using a 24mHz probe.
Study: NCT04306848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Continuous Glucose Monitoring System
Description: This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
Study: NCT05964387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
Study: NCT05039073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06362226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid/Antibiotic (Maxitrol)
Description: Group one subjects receive topical maxitrol ophthalmic ointment twice daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/Kenalog
Description: Group two undergoes treatment with a subcutaneous injection of a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination (80/20 ratio, 0.3-0.5 mL per session) administered in four sessions, spaced two weeks apart, starting within 48 hours of hospital presentation
Study: NCT05649514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Polysomnography will be performed for 24 hours at inclusion and 24 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: A full neuropsychological assessment will be performed at inclusion, 12 and 24 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires on sleep and behavioural problems
Description: Questionnaires on sleep and behavioural problems

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actimetrics
Description: Measurement of actimetrics for 14 days at inclusion and at 24 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker assay
Description: Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
Study: NCT03653702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
Study: NCT04969471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVast stent
Description: In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
Study: NCT05627362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 80 mg
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 120 mg
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 120 mg
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matched to Elafibranor 80 mg
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matched to Elafibranor 80 mg
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matched to Elafibranor 120 mg
Description: Oral Tablet
Study: NCT04850820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel essential amino acid supplementation
Description: This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amino acid supplementation (BCAA)
Description: This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric carbohydrate supplementation
Description: This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Isocaloric carbohydrate supplementation
Description: This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
Study: NCT04247022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care product (intimate gel)
Description: heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
Study: NCT05808166

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).
Description: Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).
Description: Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride injection
Description: Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
Study: NCT06535035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy After implant surgery, laser therapy (LLLT) was applied
Description: After implant surgery, laser therapy (LLLT) was applied a single session with an EPIC X Biolase diode laser (BIOLASE, Inc., USA)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: After implant surgery, After implant surgery, laser therapy (LLLT) was applied in the same manner but without activating it
Study: NCT05886257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candonilimab
Description: 10mg/kg, iv.drip, every 3 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg, iv.drip, every 3 week
Study: NCT04851457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban combination therapy
Description: Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
Study: NCT05310448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune device
Description: Wear Optune device
Study: NCT05023629

Intervention type: OTHER
Group type: OTHER
Intervention: Intracoronary balloon inflation
Description: Patients with a significant coronary artery lesion in a proximal coronary segment will undergo intracoronary balloon inflation for 90s prior to PCI.
Study: NCT05101785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain hydrochloride 2 % with epinephrine
Description: Local anesthesia infilteration in children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine chloride 4% with epinephrine
Description: Articaine chloride 4% with epinephrine